Levosert (Levonorgestrel)

Levonorgestrel is released directly into the uterine cavity from the device. The hormone thickens cervical mucus, making it hostile to sperm, suppresses the growth of the endometrium, and may inhibit ovulation, thereby preventing fertilisation and implantation.

Levosert is supplied as a single intrauterine system containing 52 mg of levonorgestrel. The device is inserted once by a qualified health professional and provides continuous hormone release for up to three years. The exact dosing schedule is determined by the prescriber.

Levosert is contraindicated in pregnancy; it must not be inserted in a woman who is pregnant or suspected to be pregnant. Women who become pregnant while the device is in place should have it removed promptly. Safety during breastfeeding has not been established, and the device is generally not recommended for lactating women.

To order Levosert, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

The primary alternative to Levosert is the copper intrauterine device, which provides non‑hormonal contraception. Compared with copper IUDs, Levosert offers hormonal regulation of bleeding and may reduce menstrual pain, but it carries hormone‑related side effects. Another hormonal alternative is Mirena, which contains a higher levonorgestrel dose (52 mg) and is approved for up to five years, whereas Levosert is approved for three years in many EU markets.

Levosert should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperature fluctuations. Handling should be performed by trained personnel using aseptic technique during insertion.

Levosert is inserted into the uterine cavity by a qualified health professional using a sterile inserter. The procedure is similar to other intrauterine devices and is performed in a clinical setting after confirming that the patient is not pregnant and has no contraindicating uterine abnormalities.

Serious risks include uterine perforation during insertion, which can damage surrounding organs; ectopic pregnancy if the device fails and fertilisation occurs outside the uterus; pelvic infection, especially if inserted during an existing infection; and spontaneous expulsion of the device, which may reduce contraceptive effectiveness.

Levosert should not be used by women who are pregnant, have a known or suspected uterine malignancy, active pelvic infection, unexplained vaginal bleeding, severe liver disease, or uterine anomalies that could impede placement. It is also contraindicated in women with a history of thromboembolic disorders related to hormonal contraception.